Bioreductively activated antitumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy

Drug Metabolism Reviews

Volumn 34, Issue 3, 2002, Pages 581-592

  Patterson, Laurence H ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antitumor; AQ4N; Bioreduction; Cytochrome P450; Prodrug

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; ALIPHATIC AMINE; AMINE OXIDE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTOCHROME B5; CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 1B1; CYTOCHROME P450 3A; CYTOCHROME P450 REDUCTASE; CYTOTOXIC AGENT; GYRASE INHIBITOR; NITRIC OXIDE SYNTHASE; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; TERTIARY AMINE; XANTHINE OXIDASE; DNA; INTERCALATING AGENT; NITROGEN OXIDE;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG METABOLISM; DRUG STRUCTURE; ENZYME SUBSTRATE; GENETIC TRANSFECTION; HUMAN; HYPOXIA; LIVER; METASTASIS; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHENOTYPE; REDUCTION; SOLID TUMOR; ANIMAL; BIOTRANSFORMATION; CELL HYPOXIA; CHEMICAL STRUCTURE; METABOLISM; MICROSOME; NEOPLASM; OXIDATION REDUCTION REACTION; REVIEW;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CELL HYPOXIA; CYTOCHROME P-450 ENZYME SYSTEM; DNA; HUMANS; INTERCALATING AGENTS; MICROSOMES; MOLECULAR STRUCTURE; NEOPLASMS; NITROGEN OXIDES; OXIDATION-REDUCTION;

EID: 0036041236     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120005659     Document Type: Conference Paper

References (46)

1. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies
2. Hypoxia and the regulation of gene expression
3. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors
4. Chemical radiosensitization of hypoxic cells
5. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia
6. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors
7. The experimental development of bioreductive drugs and their role in cancer therapy
8. Mitomycin C: A prototype bioreductive agent
9. Clinical studies with EO9, a new indoloquinone bioreductive alkylating cytotoxic agent
10. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase
11. 2-Cyclopropylindoquinones and their analogues as bioreductively activated antitumor agents: Structure-activity in vitro and efficacy in vivo
12. Tirapazamine: Laboratory data relevant to clinical activity
13. DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233); evidence for involvement of hydroxyl radical
14. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine Di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR4233; NSC 130181) in mice
15. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: A new class of bioreductive drugs
16. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs
17. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones their N-oxides
18. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation
19. Tertiary amine N-oxides as bioreductive drugs: DACA N-Oxide, nitracrine N-oxide and AQ4N
20. Enzymology of tirapazamine metabolism: A review
21. High performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide
22. Antitumor prodrug development using cytochrome P450 (CYP) mediated activation
23. Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug
24. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug
25. The human CYP3A subfamily: Practical considerations
26. Role of nitric oxide in tumor progression: Lessons from human tumors
27. Nitric oxide synthase activity in human breast cancer
28. Nitric oxide synthase activity in human gynecological cancer
29. The pharmacology and biochemistry of N-oxides
30. Pyridine nucleotide cofactor requirements of indicine N-oxide reduction by hepatic microsomal cytochrome P450
31. Reduction of tertiary amine N-oxides by cytochrome P450. Mechanism of the stimulatory effect of flavins and methyl violgen
32. Reduced nicotinamide adenine dinucleotide-dependent reduction of tertiary amine N-oxide by liver microsomal cytochrome P450
33. Partitioning between N-dealkylation and N-oxygenation in the oxidation of N,N-dialkylarylamines catalyzed by cytochrome P2B1
34. AQ4N: An alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo
35. Hirst evidence of a therapeutic gain when AQ4N or tirapazamine is combined with radiation
36. Enhancement of chemotherapy and radiotherapy of murine tumors by AQ4N, a bioreductively activated anti-tumor agent
37. DNA damage following combination of radiation with the bioreductive drug AQ4N: Possible selective toxicity to oxic and hypoxic cells
38. Co-operativity in oxidations catalyzed by cytochrome P450 3A4
39. Enzyme kinetics of cytochrome P450-mediated reaction
40. A NIH/3T3 cell-line stability expressing human cytochrome P450/3A4 used in combination with a Lacz' shuttle vector to study mutagenicity
41. Pharmacogenetic determinants of anti-cancer drug activity and toxicity
42. Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: Evolutionary, toxicological, and clinical pharmacological aspects
43. Reoxygentation and rehypoxiation in the SCCVII mouse-tumor
44. Involvement of renal cell carcinoma cytochrome P450 in bioreduction of AQ4N, a hypoxic tumor activated topoisomerase II inhibitor
45. A preclinical pharmacokinetic study of the bioreductive drug AQ4N